AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3297574 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminosalicylic acid (4-ASA) enemas, 1 g bid
Number of subjects: 47
Study 3297574 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminosalicylic acid (4-ASA) enemas, 2 g bid
Number of subjects: 47
Study 3297574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 3297574 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-ASA in open-label trial
Number of subjects: 47
Study 31411975 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA >40ng/ml, GGG5, and GGG4
Number of subjects: 201224
Study 31411975 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA, clinical tumor stage, and GGG
Number of subjects: 201224
Study 31411975 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration plot
Number of subjects: 201224
Study 31411975 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision curve analysis (DCA)
Number of subjects: 201224
Study 29550184 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon's assessment of residual disease (RD)
Number of subjects: 627
Study 29550184 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment computed tomography (CT) findings
Number of subjects: 627
Study 28089187 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal cocktail injection with morphine (10 mg)
Number of subjects: 102
Study 28089187 — intervention group
Group type: COMPARATOR
Intervention: Multimodal cocktail injection without morphine
Number of subjects: 102
Study 26018036 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mupirocin (Bactroban) twice daily and hexachlorophene (pHIsoHex) soaps daily for 7 days
Number of subjects: 49
Study 26018036 — intervention group
Group type: COMPARATOR
Intervention: Placebo similar in appearance but without specific antibacterial activity
Number of subjects: 49
Study 23812521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection (PRPplus group)
Number of subjects: 31
Study 23812521 — intervention group
Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP group)
Number of subjects: 31
Study 21489866 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 22
Study 21489866 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes-open condition
Number of subjects: 22
Study 21489866 — intervention group
Group type: COMPARATOR
Intervention: Eyes-closed placebo
Number of subjects: 22
Study 21489866 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes-open caffeine
Number of subjects: 22
Study 20025753 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface-based deformable image registration (DR)
Number of subjects: 13
Study 20025753 — intervention group
Group type: COMPARATOR
Intervention: No deformable image registration (Control)
Number of subjects: 13
Study 17020801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate surgical sealant
Number of subjects: 151
Study 17020801 — intervention group
Group type: COMPARATOR
Intervention: Control (oxidized cellulose)
Number of subjects: 151
Study 12757447 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 46
Study 12757447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 9890611 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm newborns (mean 4.6+/‐6.9 ng/mL)
Number of subjects: 326
Study 9890611 — intervention group
Group type: EXPERIMENTAL
Intervention: Term newborns (mean 19.6+/‐14.3 ng/mL)
Number of subjects: 326
Study 9890611 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 326
Study 9890611 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborns at approximately 6 days of life (mean 1.9+/‐1.1 ng/mL)
Number of subjects: 326
Study 8915402 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine powder (6 g/day)
Number of subjects: 22
Study 8915402 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 22
Study 1853148 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine, 400 mg twice a day
Number of subjects: 60
Study 1853148 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate, 1 g four times a day
Number of subjects: 60
Study 6421002 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil (D 600) 50 mg
Number of subjects: 20
Study 6421002 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil (D 600) 150 mg
Number of subjects: 20
Study 6421002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30185146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 50
Study 30185146 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 50
Study 27352907 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch tests including baseline series plus selected allergens
Number of subjects: 120
Study 27352907 — intervention group
Group type: EXPERIMENTAL
Intervention: Prick tests including standard inhalational allergens plus natural rubber latex and chlorhexidine
Number of subjects: 120
Study 24975596 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 353
Study 24975596 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 353
Study 23579360 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (FIO2 = 0.3)
Number of subjects: 8
Study 23579360 — intervention group
Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 8
Study 20537406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 450
Study 20537406 — intervention group
Group type: COMPARATOR
Intervention: Motivation enhancement therapy (MET)
Number of subjects: 450
Study 20537406 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in anxiety from baseline to 4-month follow-up
Number of subjects: 450
Study 20537406 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline anxiety
Number of subjects: 450
Study 20537406 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in marijuana use
Number of subjects: 450
Study 18467543 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + Caff (8 mg/kg BM)
Number of subjects: 7
Study 18467543 — intervention group
Group type: COMPARATOR
Intervention: CHO (4 g/kg body mass)
Number of subjects: 7
Study 15685961 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative framing
Number of subjects: 384
Study 15685961 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive framing
Number of subjects: 384
Study 15685961 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-death scenario
Number of subjects: 384
Study 15685961 — intervention group
Group type: EXPERIMENTAL
Intervention: Public property (paintings)
Number of subjects: 384
Study 15685961 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal property (money)
Number of subjects: 384
Study 15305841 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebral microdialysis and bedside biochemical analyses for monitoring cerebral energy metabolism.
Number of subjects: 0
Study 10451911 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 mg
Number of subjects: 8
Study 10451911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7598280 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (loading dose of 50-75 micrograms/kg followed by 0.5-0.75 micrograms.kg-1.min-1 for 12-24 h)
Number of subjects: 27
Study 7598280 — intervention group
Group type: COMPARATOR
Intervention: No milrinone (control group, n = 10)
Number of subjects: 27
Study 7598280 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 27
Study 2130425 — intervention group
Group type: EXPERIMENTAL
Intervention: Hidrosmin
Number of subjects: 20
Study 2130425 — intervention group
Group type: COMPARATOR
Intervention: Diosmin
Number of subjects: 20
Study 368975 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of vitamin B6 (pyridoxine)
Number of subjects: 20
Study 368975 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 31065844 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake ≥ 1.1 g/kg BW
Number of subjects: 440
Study 31065844 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher tertile of animal protein intake
Number of subjects: 440
Study 31065844 — intervention group
Group type: COMPARATOR
Intervention: Protein intake < 1.1 g/kg BW
Number of subjects: 440
Study 30933748 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually delivered treatment
Number of subjects: 557
Study 30933748 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused treatments
Number of subjects: 557
Study 30933748 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 557
Study 30933748 — intervention group
Group type: EXPERIMENTAL
Intervention: History of traumatic brain injury (TBI)
Number of subjects: 557
Study 30933748 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who did not drop out
Number of subjects: 557
Study 29237915 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular points treatment combined with acupoints application therapy
Number of subjects: 341
Study 29237915 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (control group)
Number of subjects: 341
Study 25759456 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone text messages (SMS) sent to LCS over an 8-week period
Number of subjects: 0
Study 22871333 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800 mg once-daily, individualized within 400-1200 mg range
Number of subjects: 325
Study 22871333 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Number of subjects: 325
Study 21361810 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary hygiene intervention
Number of subjects: 1029
Study 21361810 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary hygiene intervention (secular preschools only)
Number of subjects: 1029
Study 21361810 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary hygiene intervention (secular preschools)
Number of subjects: 1029
Study 21361810 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary hygiene intervention (religious preschools)
Number of subjects: 1029
Study 19701676 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasburicase 0.15 mg/kg/day
Number of subjects: 30
Study 19701676 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasburicase 0.20 mg/kg/day
Number of subjects: 30
Study 16628242 — intervention group
Group type: EXPERIMENTAL
Intervention: Luneau SA applanator
Number of subjects: 79
Study 16628242 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanator
Number of subjects: 79
Study 15166654 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption (beer, 40g/day for men, 30g/day for women)
Number of subjects: 19
Study 11201510 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy protein (80.4 mg/day)
Number of subjects: 69
Study 11201510 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-poor soy protein (4.4 mg/day)
Number of subjects: 69
Study 11201510 — intervention group
Group type: COMPARATOR
Intervention: Whey protein control
Number of subjects: 69
Study 11201510 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 69
Study 9832603 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Eating (AE)
Number of subjects: 35
Study 9832603 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Eating (PE)
Number of subjects: 35
Study 9832603 — intervention group
Group type: COMPARATOR
Intervention: Control periods during AE
Number of subjects: 35
Study 9832603 — intervention group
Group type: COMPARATOR
Intervention: Control periods during PE
Number of subjects: 35
Study 8728680 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic pyeloplasty with endoscopic suturing of the incised UPJ
Number of subjects: 8
Study 8728680 — intervention group
Group type: COMPARATOR
Intervention: Endopyelotomy (standard method)
Number of subjects: 8
Study 2156647 — intervention group
Group type: EXPERIMENTAL
Intervention: High glucose intake (105 kJ/kg)
Number of subjects: 12
Study 2156647 — intervention group
Group type: COMPARATOR
Intervention: Low glucose intake (30 kJ/kg)
Number of subjects: 12
Study 2156647 — intervention group
Group type: EXPERIMENTAL
Intervention: High nitrogen intake
Number of subjects: 12
Study 2156647 — intervention group
Group type: EXPERIMENTAL
Intervention: Added glucose intake
Number of subjects: 12
Study 396111 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol (200 mg twice daily for 8 weeks)
Number of subjects: 20
Study 396111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31619160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampakine CX516
Number of subjects: 42
Study 31619160 — intervention group
Group type: EXPERIMENTAL
Intervention: PPVT-III
Number of subjects: 42
Study 28112533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 3052
Study 28112533 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3052
Study 28112533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3052
Study 25591723 — intervention group
Group type: EXPERIMENTAL
Intervention: Second pulmonary vein isolation (PVI) procedure (group I, 48 pts)
Number of subjects: 124
Study 25591723 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic medication (group II, 46 pts)
Number of subjects: 124
Study 24256171 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 182
Study 24256171 — intervention group
Group type: COMPARATOR
Intervention: Usual care by general practitioner
Number of subjects: 182
Study 19925617 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg and 1.8 mg once-daily) plus OADs
Number of subjects: 0
Study 19925617 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg and 1.8 mg once-daily) plus metformin or metformin plus rosiglitazone
Number of subjects: 0
Study 19925617 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg and 1.8 mg once-daily) plus glimepiride
Number of subjects: 0
Study 19085384 — intervention group
Group type: EXPERIMENTAL
Intervention: Copaxone (glatiramer acetate) 20 mg weekly subcutaneous injections for 12 weeks
Number of subjects: 8
Study 19085384 — intervention group
Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 8
Study 16816306 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic mental health nurse care
Number of subjects: 247
Study 16816306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse problem-solving treatment
Number of subjects: 247
Study 16816306 — intervention group
Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 247
Study 14710057 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with epinephrine
Number of subjects: 20
Study 14710057 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution placebo with epinephrine
Number of subjects: 20
Study 10755058 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-free amino acid drink
Number of subjects: 39
Study 10755058 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 39
Study 7868327 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin temperature biofeedback with autogenic training
Number of subjects: 30
Study 7868327 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training only
Number of subjects: 30
Study 7868327 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 30
Study 2035325 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg peroral vitamin K
Number of subjects: 300
Study 2035325 — intervention group
Group type: COMPARATOR
Intervention: 1 mg intramuscular vitamin K
Number of subjects: 300
Study 7016626 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim 200 mg x 2 for 10 days
Number of subjects: 0
Study 7016626 — intervention group
Group type: COMPARATOR
Intervention: Nitrofurantoin 50 mg x 4 for 10 days
Number of subjects: 0
Study 31096941 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (healthy diet and increased physical activity)
Number of subjects: 260
Study 31096941 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 260
Study 28701602 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 mcg/kg) over 10 min before propofol (1 mg/kg)
Number of subjects: 500
Study 28701602 — intervention group
Group type: COMPARATOR
Intervention: Propofol (1 mg/kg) only
Number of subjects: 500
Study 25791716 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 185
Study 25791716 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tissue-type plasminogen activator
Number of subjects: 185
Study 23398953 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil-based lipid emulsion (FOLE) (Omegaven(®))
Number of subjects: 63
Study 23398953 — intervention group
Group type: COMPARATOR
Intervention: Control lipid emulsion (MCT/LCT; Lipovenos MCT(®))
Number of subjects: 63
Study 20861241 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable Stimulation (AS)
Number of subjects: 110
Study 20861241 — intervention group
Group type: COMPARATOR
Intervention: Preset Stimulation (PS)
Number of subjects: 110
Study 20861241 — intervention group
Group type: COMPARATOR
Intervention: Medical Management (MM)
Number of subjects: 110
Study 19725966 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate monotherapy
Number of subjects: 91
Study 19725966 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine combination therapy
Number of subjects: 91
Study 19725966 — intervention group
Group type: COMPARATOR
Intervention: Non-febrile healthy controls
Number of subjects: 91
Study 17541696 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 3
Study 17541696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 15093200 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy and radiation therapy
Number of subjects: 0
Study 15093200 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment with chemotherapy first followed by radiation
Number of subjects: 0
Study 11918235 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal resection with contralateral hemithyroidectomy (SHT)
Number of subjects: 152
Study 11918235 — intervention group
Group type: COMPARATOR
Intervention: Subtotal resection on both sides (STT)
Number of subjects: 152
Study 9917601 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral head diameter of 22 mm with acetabular component outer diameter of 56 mm or larger
Number of subjects: 338
Study 9917601 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral head diameter of 28 mm with acetabular component outer diameter of 62 mm or larger
Number of subjects: 338
Study 9917601 — intervention group
Group type: COMPARATOR
Intervention: Femoral head diameter of 28 mm with acetabular component outer diameter of 60 mm or smaller
Number of subjects: 338
Study 7852615 — intervention group
Group type: EXPERIMENTAL
Intervention: Plax (Colgate) prebrushing rinse
Number of subjects: 19
Study 7852615 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 19
Study 2901270 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.3 mg kg‐1
Number of subjects: 0
Study 2901270 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 0
Study 31990700 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesional skin
Number of subjects: 48
Study 31990700 — intervention group
Group type: COMPARATOR
Intervention: Perilesional normal skin
Number of subjects: 48
Study 31990700 — intervention group
Group type: EXPERIMENTAL
Intervention: Electron microscopy
Number of subjects: 48
Study 29474602 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis patients with BTP concentration >7.96 mg/L
Number of subjects: 3869
Study 29474602 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography patients with BTP concentration >0.67 mg/L
Number of subjects: 3869
Study 26707677 — intervention group
Group type: EXPERIMENTAL
Intervention: Divergent thinking assessed by the alternative-uses-task (AUT)
Number of subjects: 49
Study 26707677 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergent thinking assessed by the Intelligenz-Struktur-Test-2000 (IST)
Number of subjects: 49
Study 26707677 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor adaptation assessed by a pointing task with 60° rotated visual feedback
Number of subjects: 49
Study 25563312 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (GCV) 1000 mg 3 times per day for 8 weeks, plus topical 0.15% GCV ophthalmic gel and 0.1% fluorometholone eye drops.
Number of subjects: 173
Study 25563312 — intervention group
Group type: COMPARATOR
Intervention: Topical acyclovir (ACV) with the same ophthalmic gel and eye drops, plus oral ACV 400 mg 5 times a day for 10 weeks, then 400 mg 2 times per day for 6 months.
Number of subjects: 173
Study 25563312 — intervention group
Group type: COMPARATOR
Intervention: Negative control (placebo) group with topical 0.15% GCV ophthalmic gel and 0.1% fluorometholone eye drops.
Number of subjects: 173
Study 23761134 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmeal walking for 15 min
Number of subjects: 10
Study 23761134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained morning walking for 45 min
Number of subjects: 10
Study 23761134 — intervention group
Group type: COMPARATOR
Intervention: Control day (no walking)
Number of subjects: 10
Study 21168907 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric EvoCeram
Number of subjects: 28
Study 21168907 — intervention group
Group type: COMPARATOR
Intervention: Filtek Z250 (Control)
Number of subjects: 28
Study 21168907 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Supreme
Number of subjects: 28
Study 21168907 — intervention group
Group type: EXPERIMENTAL
Intervention: Admira (Ormocer)
Number of subjects: 28
Study 18439113 — intervention group
Group type: COMPARATOR
Intervention: Tianeptine
Number of subjects: 21
Study 18439113 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 21
Study 18439113 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 21
Study 18439113 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 21